Kaleido Stock Today

KLDO -  USA Stock  

USD 1.74  0.15  7.94%

Market Performance
0 of 100
Odds Of Distress
Over 81
Kaleido Biosciences is selling for 1.74 as of the 28th of January 2022. This is a -7.94% down since the beginning of the trading day. The stock's open price was 1.89. Kaleido Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Kaleido Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of February 2020 and ending today, the 28th of January 2022. Click here to learn more.
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 42.59 M outstanding shares of which 2.21 M shares are now shorted by private and institutional investors with about 15.12 trading days to cover. More on Kaleido Biosciences

Kaleido Biosciences Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Kaleido Biosciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Kaleido Biosciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Kaleido Biosciences generated a negative expected return over the last 90 days
Kaleido Biosciences has high historical volatility and very poor performance
Kaleido Biosciences may become a speculative penny stock
Kaleido Biosciences has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 855 K. Net Loss for the year was (90.03 M) with loss before overhead, payroll, taxes, and interest of (54.99 M).
Kaleido Biosciences currently holds about 55.66 M in cash with (71.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31.
Kaleido Biosciences has a frail financial position based on the latest SEC disclosures
Over 82.0% of the company shares are owned by institutional investors
Latest headline from www.marketscreener.com: Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohns and Colitis Congress - marketscreener.com
Kaleido Biosciences Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Kaleido Biosciences SEC Filings
Kaleido Biosciences SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameKaleido Biosciences
Chairman of the Board, CEOMike Bonney  (View All)
Average Analyst Recommendation
Analysts covering Kaleido Biosciences report their recommendations after researching Kaleido Biosciences' financial statements, talking to executives and customers, or listening in on Kaleido Biosciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Kaleido Biosciences. The Kaleido consensus assessment is calculated by taking the average forecast from all of the analysts covering Kaleido Biosciences.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Kaleido Biosciences based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Kaleido Biosciences financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares41.5 M38.5 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted41.5 M38.5 M
Significantly Up
Increasing
Slightly volatile
Total Assets73.2 M68.2 M
Notably Up
Increasing
Slightly volatile
Total Liabilities41.3 M44.7 M
Significantly Down
Increasing
Slightly volatile
Current Assets62.3 M56 M
Moderately Up
Increasing
Slightly volatile
Current Liabilities16.2 M19.2 M
Fairly Down
Increasing
Slightly volatile
Total Debt23 M24.2 M
Notably Down
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.01250.0126
Slightly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Kaleido Biosciences' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Kaleido Biosciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Kaleido Biosciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kaleido Biosciences' financial leverage. It provides some insight into what part of Kaleido Biosciences' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Kaleido Biosciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Kaleido Biosciences deploys its capital and how much of that capital is borrowed.
Liquidity
Kaleido Biosciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 21.52 M in liabilities with Debt to Equity (D/E) ratio of 0.74, which is about average as compared to similar companies. Kaleido Biosciences has a current ratio of 2.97, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(59.74 Million)Share
Kaleido Biosciences (KLDO) is traded on NASDAQ Exchange in USA. It is located in 65 Hayden Avenue and employs 82 people. Kaleido Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 92 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kaleido Biosciences's market, we take the total number of its shares issued and multiply it by Kaleido Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Kaleido Biosciences conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 42.59 M outstanding shares of which 2.21 M shares are now shorted by private and institutional investors with about 15.12 trading days to cover. Kaleido Biosciences currently holds about 55.66 M in cash with (71.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31.
Check Kaleido Biosciences Probability Of Bankruptcy
Ownership
Kaleido Biosciences maintains a total of fourty-two million five hundred ninety thousand outstanding shares. The majority of Kaleido Biosciences outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kaleido Biosciences to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kaleido Biosciences. Please pay attention to any change in the institutional holdings of Kaleido Biosciences as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Kaleido Ownership Details

Kaleido Stock Price Odds Analysis

What are Kaleido Biosciences' target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Kaleido Biosciences jumping above the current price in 90 days from now is roughly 96.0%. The Kaleido Biosciences probability density function shows the probability of Kaleido Biosciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Kaleido Biosciences has a beta of 0.9453. This indicates Kaleido Biosciences market returns are very sensitive to returns on the market. As the market goes up or down, Kaleido Biosciences is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Kaleido Biosciences is significantly underperforming DOW.
 Odds Down 1.74HorizonTargetOdds Up 1.74 
3.60%90 days
 1.74 
96.39%
Based on a normal probability distribution, the odds of Kaleido Biosciences to move above the current price in 90 days from now is roughly 96.0 (This Kaleido Biosciences probability density function shows the probability of Kaleido Stock to fall within a particular range of prices over 90 days) .

Kaleido Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Kaleido Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kaleido Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kaleido Biosciences' value.
InstituionSecurity TypeTotal SharesValue
Baillie Gifford CoCommon Shares721.5 K1.7 M
Endurance Wealth Management IncCommon Shares1000K
View Kaleido Biosciences Diagnostics

Kaleido Biosciences Historical Income Statement

Kaleido Biosciences Income Statement is one of the three primary financial statements used for reporting Kaleido's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Kaleido Biosciences revenue and expense. Kaleido Biosciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Kaleido Biosciences Interest Expense is quite stable at the moment as compared to the past year. The company's current value of Interest Expense is estimated at 3.48 Million. Weighted Average Shares is expected to rise to about 41.5 M this year, although the value of Consolidated Income will most likely fall to (79.3 M). View More Fundamentals

Kaleido Stock Against Markets

Picking the right benchmark for Kaleido Biosciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Kaleido Biosciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Kaleido Biosciences is critical whether you are bullish or bearish towards Kaleido Biosciences at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kaleido Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Diagnostics Now

   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Module

Kaleido Biosciences Corporate Directors

Kaleido Biosciences corporate directors refer to members of a Kaleido Biosciences board of directors. The board of directors generally takes responsibility for the Kaleido Biosciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Kaleido Biosciences' board members must vote for the resolution. The Kaleido Biosciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Grady Burnett - DirectorProfile
Bonnie Bassler - DirectorProfile
John Sculley - DirectorProfile
Theo MelasKyriazi - Independent DirectorProfile
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Is Kaleido Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kaleido Biosciences. If investors know Kaleido will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kaleido Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.